Analysts Offer Predictions for CNTA Q3 Earnings

Centessa Pharmaceuticals plc (NASDAQ:CNTA) – Research analysts at Leerink Partnrs issued their Q3 2025 earnings estimates for shares of Centessa Pharmaceuticals in a note issued to investors on Monday, March 24th. Leerink Partnrs analyst D. Risinger anticipates that the company will earn ($0.40) per share for the quarter. The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.60) per share. Leerink Partnrs also issued estimates for Centessa Pharmaceuticals’ FY2025 earnings at ($1.57) EPS, FY2026 earnings at ($1.71) EPS, FY2027 earnings at ($1.84) EPS, FY2028 earnings at ($2.06) EPS and FY2029 earnings at $0.49 EPS.

Other equities research analysts have also recently issued reports about the stock. TD Cowen began coverage on shares of Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating on the stock. Morgan Stanley reissued an “overweight” rating and set a $27.00 target price on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Finally, Guggenheim restated a “buy” rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $26.00.

Centessa Pharmaceuticals Trading Up 0.6 %

Shares of Centessa Pharmaceuticals stock opened at $14.59 on Thursday. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The firm has a market cap of $1.92 billion, a price-to-earnings ratio of -9.54 and a beta of 1.54. The business has a fifty day simple moving average of $16.48 and a 200-day simple moving average of $16.41. Centessa Pharmaceuticals has a fifty-two week low of $7.75 and a fifty-two week high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.04.

Insider Buying and Selling at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, CEO Saurabh Saha sold 55,000 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $15.77, for a total transaction of $867,350.00. Following the sale, the chief executive officer now directly owns 429,398 shares of the company’s stock, valued at $6,771,606.46. The trade was a 11.35 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Karen M. Anderson sold 30,526 shares of the stock in a transaction on Friday, February 7th. The shares were sold at an average price of $19.03, for a total value of $580,909.78. Following the completion of the sale, the insider now owns 54,322 shares of the company’s stock, valued at $1,033,747.66. The trade was a 35.98 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 260,168 shares of company stock valued at $4,309,568. 11.59% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Janus Henderson Group PLC lifted its position in shares of Centessa Pharmaceuticals by 279.2% in the fourth quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company’s stock worth $82,218,000 after purchasing an additional 3,614,623 shares in the last quarter. Foresite Capital Management VI LLC acquired a new position in Centessa Pharmaceuticals in the 4th quarter valued at approximately $20,994,000. Franklin Resources Inc. lifted its position in Centessa Pharmaceuticals by 99.1% in the 3rd quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock worth $38,360,000 after buying an additional 1,145,823 shares in the last quarter. Point72 Asset Management L.P. lifted its position in Centessa Pharmaceuticals by 54.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company’s stock worth $43,423,000 after buying an additional 953,659 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its stake in shares of Centessa Pharmaceuticals by 22.0% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company’s stock valued at $85,744,000 after buying an additional 924,027 shares during the period. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.